Effect of Src tyrosine kinase inhibition on secretion of MMP-2 and MMP-9 by non-small cell lung cancer cells

Chinese Journal of Lung Cancer

Volumn 14, Issue 1, 2011, Pages 13-17

  Zheng, Rui ^a   Qin, Xiaosong ^a   Li, Wenjie ^a   Kang, Jian ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Invasion; Lung neoplasms; MMP 2; MMP 9; Src tyrosine kinase

Indexed keywords

GELATINASE A; GELATINASE B; PROTEIN TYROSINE KINASE;

ARTICLE; CELL INVASION; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; IN VITRO STUDY; LUNG NON SMALL CELL CANCER;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PROTEIN KINASE INHIBITORS; SRC-FAMILY KINASES;

EID: 78751682845     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2011.01.03     Document Type: Article

References (17)

1. Johansson N, Ahonen M, Kahari VM. Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci, 2000, 57(l): 5-15.
2. O'Connor CM, FitzGerald MX. Matrix metalloproteases and lung disease. Thorax, 1994, 49(6): 602-609.
3. Tang XJ, Zhou QH. Relationship between matrix metalloproteases and lung cancer invasion and metastasis. Chin J Lung Cancer, 2001, 4(2): 116-120.
4. Herbst RS, Yano S, Kuniyasu H, et al. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res, 2000, 6(3): 790-797.
5. Martinella-Catusse C, Nawrocki B, Gilles C, et al. Matrix metalloproteinases in bronchopulmonary carcinomas. Histol Histopathol, 1999, 14(3): 839-843.
6. Aleshin A, Finn RS. SRC: a century of science brought to the clinic. Neoplasia, 2010, 12(8): 599-607.
7. Ito H, Gardner-Thorpe J, Zinner MJ, et al. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery, 2003, 134(2): 221-226. (Pubitemid 37070342)
8. Recchia I, Rucci N, Festuccia C, et al. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer, 2003, 39(13): 1927-1935.
9. Shiraga M, Yano S, Yamamoto A, et al. Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines. Cancer Res, 2002, 62(20): 5967-5973.
10. Zheng R, Wen H, Seiji Y, et al. Effect of Src on proliferation and invasion of lung adenocarcinoma A549 cell line. ChinJ Cancer Prev Treat, 2005, 12(10): 746-749.
11. Yang JH, Wang D, Wang XY. Metalloproteinases and their inhibitors in lung cancer. Chin J Lung Cancer, 2002, 5(1): 76-78.
12. Iniesta P, Morán A, De Juan C, et al. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol Rep, 2007, 17(1): 217-223.
13. Leinonen T, Pirinen R, Bohm J, et al. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis. Lung Cancer, 2006, 51(3): 313-321.
14. Kopczynska E, Dancewicz M, Kowalewski J, et al. The serum concentration of metalloproteinase 9 and 2 in non-small cell lung cancer patients. Pol MerkurLekarski, 2007, 22(132): 539-541.
15. Lu HJ, Guo CB, Jin XQ, et al. The role of matrix metalloproteinase expression in lung cancer metastasis. Chin Clin Oncol, 2006, 11(7): 486-490.
16. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J, 1999, 13(8): 781-792.
17. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta, 2002, 1602(2): 114-130.